select trial semaglutide nejm New in the May 29, 2025, issue of NEJM: Sotatercept in Pulmonary Arterial Hypertension (ZENITH phase 3 trial) https://nej.md/4iYkLbj Oral and Cardiovascular Outcomes (SOUL trial) https://nej.md/4hHII5M Upadacitinib for Giant-Cell Arteritis Semaglutide and Cardiovascular Outcomes in

Description

A combination of both

References 1.Medications containing semaglutide marketed for type 2 diabetes or weight loss

What To Know Novo Nordisk also said in its announcement on Monday that for existing self-pay patients using the injections, costs will also be slashed

[1] [3] According to its Summary of Product Characteristics (SmPC), it is indicated to improve glycaemic control in adults when diet and exercise alone prove insufficient, either as monotherapy when metformin is inappropriate or as an add-on therapy with other diabetes medications